封面
市場調查報告書
商品編碼
1702334

乾皮症的全球市場 (~2032年):治療 (潤膚劑、保濕劑、濕潤劑·油·其他)·原因 (濕疹·乾癬·糖尿病·甲狀腺機能低下症·老齡化·其他)、終端用戶 (醫院·皮膚科診所·居家醫療) 各

Global Xerosis Market Information by Treatment (emollients, moisturizer, humidifier, oils, others) by Causes (eczema, psoriasis, diabetes, hypothyroidism, aging, others) by End Users (hospitals, dermatology clinics, home care) Forecast till 2032

出版日期: | 出版商: Market Research Future | 英文 188 Pages | 訂單完成後即時交付

價格

預計從 2024 年到 2032 年,皮膚乾燥症市場規模的複合年增長率將達到 7.71%。皮膚乾燥症的傳統治療包括使用潤膚劑和保濕劑。

此外,改善生活習慣也是有效的。由於老化和糖尿病引起的荷爾蒙變化會改變汗腺和皮脂腺,增加皮膚乾燥症的風險。凡士林、植物油、礦物油等高封閉性皮膚屏障產品都有良好的效果。羊毛脂是從羊毛中提取的天然脂質,可取代人體皮膚中的脂質,是治療乾燥症最成功的藥物之一。羊毛脂的主要缺點是它可能引起過敏,而且它是一種厚厚的蠟狀物質,難以塗抹。

區域分析

由於藥物使用量和醫療支出的增加,美國佔據了乾皮症市場的最大佔有率。美國加速向市場推出新技術和新設備也是乾皮症產業發展的主要動力。歐洲是第二大市場,受高可支配收入和不斷增強的意識推動。預計亞太地區將擁有最大的潛力,其中以中國和印度為首。

本報告提供全球乾皮症的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,市場規模的轉變·預測,各種區分·地區/各主要國家的明細,競爭環境,主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 市場概要

第3章 調查手法

第4章 市場動態

  • 促進因素
    • 提高認識並改善診斷
    • 創新的產品配方
    • 可支配收入和皮膚護理支出增加
  • 阻礙因素
    • 與乾皮症藥物相關的副作用
  • 機會
    • 老年人口增加
    • 加強乾性肌膚的自我照顧習慣
    • 正在進行的臨床試驗和大學研究

市場要素分析

  • 波特的五力分析
  • COVID-19對全球乾皮症治療市場帶來的影響
  • 流行病學分析
  • 市場趨勢

第5章 全球乾皮症治療市場:各類型

  • 概要
  • 藥物
    • 抗組織胺藥
    • 皮質類固醇
    • Calcineurin抑制劑
    • 抗發炎
    • 免疫調節藥
    • 其他
  • 個人保健產品

第6章 全球乾皮症治療市場:不同形態

  • 概要
  • 化妝水
  • 乳霜
  • 軟膏
  • 泡沫沐浴乳
  • 其他

第7章 全球乾皮症治療市場:各年齡層

  • 概要
  • 兒童
  • 成人
  • 老年人

第8章 全球乾皮症治療市場:性別

  • 概要
  • 男性
  • 女性

第9章 全球乾皮症治療市場:各流通管道

  • 概要
  • 線上
  • 離線

第10章 全球乾皮症治療市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 俄羅斯
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 馬來西亞
    • 泰國
    • 印尼
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他
  • 中東·非洲
    • GCC各國
    • 南非
    • 其他

第11章 競爭情形

  • 2023年的市場佔有率分析
  • 競爭儀表板
  • 上市公司的股票摘要
  • 比較分析:主要企業的財務
  • 主要的展開與成長策略

第12章 企業簡介

  • AMGEN INC
  • PROCTER & GAMBLE
  • UNILEVER
  • PFIZER INC.
  • CIPLA
  • BAYER AG
  • JOHNSON & JOHNSON INC.
  • GALDERMA
  • DR. REDDY'S LABORATORIES LTD.
  • THORNTON & ROSS LTD.

第13章 資料的引用

Product Code: MRFR/Pharma/2722-HCR

Market Overview

The Xerosis Market is expected to develop at a compound annual growth rate (CAGR) of 7.71% from 2024 to 2032. Xerosis, also known as xeroderma, is a skin disorder characterized by excessive dryness caused by over-cleansing, excessive showering, living in low-humidity areas, dehydration, prolonged sun exposure, ageing, and so on. Xerosis most typically affects the scalp, lower legs, arms, and thighs, with symptoms including scaling (visible peeling of the outer skin layer), itching, and skin cracking. Other symptoms include dry, itchy, and scaly skin, flaky skin, and irritated red skin. Xerosis is common throughout the winter because the cold, dry air causes the skin to lose moisture. Xerosis can also be caused by a vitamin A or vitamin D deficiency, systemic disease, or drug adverse effects. The conventional treatment for xerosis is to apply emollients, moisturizers, and so on.

Xerosis also responds favorable to lifestyle adjustments. Hormonal changes caused by aging, diabetes, and other conditions alter sweat and sebaceous glands, increasing the risk of Xerosis. Petrolatum, vegetable oils, mineral oil, and other highly occlusive skin barrier products produce good outcomes. Lanolin, a natural lipid obtained from sheep's wool, replaces the lipids found in human skin and is one of the most successful therapies for xeroderma. The main disadvantages of lanolin are that it is a common allergy and that it is a thick waxy substance that is difficult to apply.

Market Segmentation

The global xerosis market is categorized by therapy, cause, and end user.

The market is divided into therapeutic categories such as emollients, moisturizers, humidifiers, oils, and others.

The market has been classified into causes such as eczema, psoriasis, diabetes, hypothyroidism, aging, and others.

The market has been categorized by end users into hospitals, dermatological clinics, and home care.

Regional analysis.

The United States has the highest Xerosis market share because to increased medicine use and healthcare expenditure. The speedier market adoption of new technology and gadgets in the United States is another key driver of the Xerosis industry. Europe is the second largest market, owing to high disposable income and increased awareness. The Asia-Pacific area is predicted to have the biggest future potential, driven by China and India.

The Gulf nations, particularly Saudi Arabia and the United Arab Emirates, dominate the Middle East and Africa market. Africa's Xerosis market is predicted to develop moderately due to weak economic and political situations, as well as low healthcare penetration. Market Research Future's report on the Global Xerosis market includes extensive primary research as well as rigorous qualitative and quantitative analysis by various industry professionals and key opinion leaders to acquire a better understanding of the market and industry performance.

Key Players

Procter & Gamble, Alba Botanica, Avalon Organics, Johnson & Johnson Consumer Inc., Galderma Laboratories, Clarins, Unilever, Hempz, L'Oreal, Avon, Croda International Plc, Beiersdorf, Estee Lauder, United-Guardian, Inc., Dow Corning Corp., and others are the market leaders in Xerosis.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
  • 3.7 DATA FORECASTING
    • 3.7.1 DATA FORECASTING TYPE
  • 3.8 DATA MODELING
    • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.8.2 DATA MODELING:
  • 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 RISING AWARENESS AND IMPROVED DIAGNOSIS
    • 4.2.2 INNOVATIVE PRODUCT FORMULATIONS
    • 4.2.3 RISE IN DISPOSABLE INCOME AND SPENDING ON SKINCARE
  • 4.3 RESTRAINTS
    • 4.3.1 SIDE EFFECTS ASSOCIATED WITH THE XEROSIS TREATMENT DRUGS
  • 4.4 OPPORTUNITY
    • 4.4.1 GROWING GERIATRIC POPULATION
    • 4.4.2 INCREASE IN SELF-CARE PRACTICES FOR XEROSIS
    • 4.4.3 ONGOING CLINICAL TRIALS AND UNIVERSITIES STUDIES

MARKET FACTOR ANALYSIS

  • 4.5 PORTER'S FIVE FORCES MODEL
    • 4.5.1 THREAT OF NEW ENTRANTS
    • 4.5.2 BARGAINING POWER OF SUPPLIERS
    • 4.5.3 THREAT OF SUBSTITUTES
    • 4.5.4 BARGAINING POWER OF BUYERS
    • 4.5.5 INTENSITY OF RIVALRY
  • 4.6 IMPACT OF COVID-19 ON GLOBAL XEROSIS TREATMENT MARKET
  • 4.7 EPIDEMIOLOGY ANALYSIS
  • 4.8 MARKET TRENDS

5 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE

  • 5.1 OVERVIEW
  • 5.2 MEDICATION
    • 5.2.1 ANTIHISTAMINES
    • 5.2.2 CORTICOSTEROIDS
    • 5.2.3 CALCINEURIN INHIBITORS
    • 5.2.4 ANTI-INFLAMMATORY
    • 5.2.5 IMMUNOMODULATORS
    • 5.2.6 OTHERS
  • 5.3 PERSONAL CARE PRODUCTS

6 GLOBAL XEROSIS TREATMENT MARKET, BY FORM

  • 6.1 OVERVIEW
  • 6.2 TABLETS
  • 6.3 LOTION
  • 6.4 CREAM
  • 6.5 OINTMENT
  • 6.6 SHOWER FOAMS
  • 6.7 OTHERS

7 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP

  • 7.1 OVERVIEW
  • 7.2 PAEDIATRICS
  • 7.3 ADULTS
  • 7.4 ELDERLY

8 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER

  • 8.1 OVERVIEW
  • 8.2 MALE
  • 8.3 FEMALE

9 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 OVERVIEW
  • 9.2 ONLINE
  • 9.3 OFFLINE

10 GLOBAL XEROSIS TREATMENT MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 US
    • 10.2.2 CANADA
  • 10.3 EUROPE
    • 10.3.1 GERMANY
    • 10.3.2 FRANCE
    • 10.3.3 UK
    • 10.3.4 SPAIN
    • 10.3.5 ITALY
    • 10.3.6 RUSSIA
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 CHINA
    • 10.4.2 INDIA
    • 10.4.3 JAPAN
    • 10.4.4 SOUTH KOREA
    • 10.4.5 MALAYSIA
    • 10.4.6 THAILAND
    • 10.4.7 INDONESIA
    • 10.4.8 REST OF ASIA PACIFIC
  • 10.5 SOUTH AMERICA
    • 10.5.1 BRAZIL
    • 10.5.2 MEXICO
    • 10.5.3 ARGENTINA
    • 10.5.4 REST OF SOUTH AMERICA
  • 10.6 MIDDLE EAST AND AFRICA
    • 10.6.1 GCC COUNTRIES
    • 10.6.2 SOUTH AFRICA
    • 10.6.3 REST OF MEA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS, 2023
  • 11.3 COMPETITOR DASHBOARD
  • 11.4 PUBLIC PLAYERS STOCK SUMMARY
  • 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
  • 11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.1.1 PRODUCT LAUNCH

12 COMPANY PROFILES

  • 12.1 AMGEN INC
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 FINANCIAL OVERVIEW
    • 12.1.3 PRODUCTS OFFERED
    • 12.1.4 KEY DEVELOPMENTS
    • 12.1.5 SWOT ANALYSIS
    • 12.1.6 KEY STRATEGIES
  • 12.2 PROCTER & GAMBLE
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 FINANCIAL OVERVIEW
    • 12.2.3 PRODUCTS OFFERED
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
    • 12.2.6 KEY STRATEGIES
  • 12.3 UNILEVER
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 FINANCIAL OVERVIEW
    • 12.3.3 PRODUCTS OFFERED
    • 12.3.4 KEY DEVELOPMENTS
    • 12.3.5 KEY STRATEGIES
  • 12.4 PFIZER INC.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 FINANCIAL OVERVIEW
    • 12.4.3 PRODUCTS OFFERED
    • 12.4.4 KEY DEVELOPMENTS
    • 12.4.5 SWOT ANALYSIS
    • 12.4.6 KEY STRATEGIES
  • 12.5 CIPLA
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 FINANCIAL OVERVIEW
    • 12.5.3 PRODUCTS OFFERED
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 KEY STRATEGIES
  • 12.6 BAYER AG
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 FINANCIAL OVERVIEW
    • 12.6.3 PRODUCTS OFFERED
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 SWOT ANALYSIS
    • 12.6.6 KEY STRATEGY
  • 12.7 JOHNSON & JOHNSON INC.
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 FINANCIAL OVERVIEW
    • 12.7.3 PRODUCTS OFFERED
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 SWOT ANALYSIS
    • 12.7.6 KEY STRATEGIES
  • 12.8 GALDERMA
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 FINANCIAL OVERVIEW
    • 12.8.3 PRODUCT OFFERED
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 KEY STRATEGIES
  • 12.9 DR. REDDY'S LABORATORIES LTD.
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 FINANCIAL OVERVIEW
    • 12.9.3 PRODUCT OFFERED
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 KEY STRATEGIES
  • 12.10 THORNTON & ROSS LTD.
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 FINANCIAL OVERVIEW
    • 12.10.3 PRODUCT OFFERED
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 KEY STRATEGIES

13 DATA CITATIONS

LIST OF TABLES

  • TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 3 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 4 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 5 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 6 GLOBAL XEROSIS TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 7 GLOBAL XEROSIS TREATMENT MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 8 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 9 GLOBAL XEROSIS TREATMENT MARKET, FOR IMMUNOMODULATORS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 10 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 11 GLOBAL XEROSIS TREATMENT MARKET, FOR PERSONAL CARE PRODUCTS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 12 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 13 GLOBAL XEROSIS TREATMENT MARKET, FOR TABLETS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 14 GLOBAL XEROSIS TREATMENT MARKET, FOR LOTION, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 15 GLOBAL XEROSIS TREATMENT MARKET, FOR CREAM, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 16 GLOBAL XEROSIS TREATMENT MARKET, FOR OINTMENT, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 17 GLOBAL XEROSIS TREATMENT MARKET, FOR SHOWER FOAMS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 18 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 19 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 20 GLOBAL XEROSIS TREATMENT MARKET, FOR PAEDIATRICS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 21 GLOBAL XEROSIS TREATMENT MARKET, FOR ADULTS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 22 GLOBAL XEROSIS TREATMENT MARKET, FOR ELDERLY, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 23 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 24 GLOBAL XEROSIS TREATMENT MARKET, FOR MALE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 25 GLOBAL XEROSIS TREATMENT MARKET, FOR FEMALE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 26 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 27 GLOBAL XEROSIS TREATMENT MARKET, FOR ONLINE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 28 GLOBAL XEROSIS TREATMENT MARKET, FOR OFFLINE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 29 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 30 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 31 NORTH AMERICA XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 32 NORTH AMERICA XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 33 NORTH AMERICA XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 34 NORTH AMERICA XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 35 NORTH AMERICA XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 36 NORTH AMERICA XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 37 US: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 38 US: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 39 US: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 40 US: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 41 US: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 42 US: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 43 CANADA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 44 CANADA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 45 CANADA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 46 CANADA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 47 CANADA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 48 CANADA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 49 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 50 EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 51 EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 52 EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 53 EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 54 EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 55 EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 56 GERMANY: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 57 GERMANY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 58 GERMANY: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 59 GERMANY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 60 GERMANY: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 61 GERMANY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 62 FRANCE: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 63 FRANCE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 64 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 65 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 66 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 67 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 68 UK: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 69 UK: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 70 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 71 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 72 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 73 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 74 SPAIN: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 75 SPAIN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 76 SPAIN: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 77 SPAIN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 78 SPAIN: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 79 SPAIN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 80 ITALY: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 81 ITALY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 82 ITALY: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 83 ITALY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 84 ITALY: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 85 ITALY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 86 RUSSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 87 RUSSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 88 RUSSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 89 RUSSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 90 RUSSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 91 RUSSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 92 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 93 REST OF EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 94 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 95 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 96 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 97 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 98 ASIA PACIFIC XEROSIS TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 105 CHINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 106 CHINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 107 CHINA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 108 CHINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 109 CHINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 110 CHINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 111 INDIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 112 INDIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 113 INDIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 114 INDIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 115 INDIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 116 INDIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 117 JAPAN: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 118 JAPAN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 119 JAPAN: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 120 JAPAN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 121 JAPAN: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 122 JAPAN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 123 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 124 SOUTH KOREA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 125 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 126 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 127 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 128 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 129 MALAYSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 130 MALAYSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 131 MALAYSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 132 MALAYSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 133 MALAYSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 134 MALAYSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 135 THAILAND: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 136 THAILAND: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 137 THAILAND: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 138 THAILAND: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 139 THAILAND: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 140 THAILAND: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 141 INDONESIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 142 INDONESIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 143 INDONESIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 144 INDONESIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 145 INDONESIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 146 INDONESIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 148 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 149 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 150 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 151 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 152 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 153 SOUTH AMERICA XEROSIS TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 154 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 155 SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 156 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 157 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 158 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 159 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 160 BRAZIL: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 161 BRAZIL: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 162 BRAZIL: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 163 BRAZIL: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 164 BRAZIL: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 165 BRAZIL: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 166 MEXICO: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 167 MEXICO: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 168 MEXICO: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 169 MEXICO: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 170 MEXICO: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 171 MEXICO: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 172 ARGENTINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 173 ARGENTINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 174 ARGENTINA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 175 ARGENTINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 176 ARGENTINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 177 ARGENTINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 178 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 179 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 180 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 181 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 182 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 183 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 184 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 185 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 186 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 187 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 188 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 189 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 190 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 191 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 193 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 194 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 195 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 196 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 197 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 198 SOUTH AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 199 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 200 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 201 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 202 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 203 REST OF MEA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 204 REST OF MEA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 205 REST OF MEA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
  • TABLE 206 REST OF MEA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
  • TABLE 207 REST OF MEA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
  • TABLE 208 REST OF MEA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 209 PUBLIC PLAYERS STOCK SUMMARY
  • TABLE 210 PRODUCT LAUNCH
  • TABLE 211 AMGEN INC.: PRODUCTS OFFERED
  • TABLE 212 AMGEN INC.: KEY DEVELOPMENTS
  • TABLE 213 PROCTER & GAMBLE: PRODUCTS OFFERED
  • TABLE 214 PROCTER & GAMBLE: KEY DEVELOPMENTS
  • TABLE 215 UNILEVER: PRODUCTS OFFERED
  • TABLE 216 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 217 CIPLA: PRODUCTS OFFERED
  • TABLE 218 BAYER AG: PRODUCTS OFFERED
  • TABLE 219 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED
  • TABLE 220 GALDERMA: PRODUCTS OFFERED
  • TABLE 221 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED
  • TABLE 222 THORNTON & ROSS LTD.: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL XEROSIS MARKET: STRUCTURE
  • FIGURE 2 GLOBAL XEROSIS TREATMENT: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL XEROSIS TREATMENT MARKET
  • FIGURE 6 GLOBAL XEROSIS TREATMENT MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
  • FIGURE 7 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2023 & 2032 (USD MILLION)
  • FIGURE 8 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY TYPE, 2023
  • FIGURE 9 GLOBAL XEROSIS TREATMENT MARKET, FORM SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
  • FIGURE 10 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2023 & 2032 (USD MILLION)
  • FIGURE 11 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY FORM, 2023
  • FIGURE 12 GLOBAL XEROSIS TREATMENT MARKET, AGE GROUP SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
  • FIGURE 13 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION)
  • FIGURE 14 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY AGE GROUP, 2023
  • FIGURE 15 GLOBAL XEROSIS TREATMENT MARKET, GENDER SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
  • FIGURE 16 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2023 & 2032 (USD MILLION)
  • FIGURE 17 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY GENDER, 2023
  • FIGURE 18 GLOBAL XEROSIS TREATMENT MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
  • FIGURE 19 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION)
  • FIGURE 20 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023
  • FIGURE 21 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2023 & 2032 (USD MILLION)
  • FIGURE 22 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY REGION, 2023
  • FIGURE 23 NORTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
  • FIGURE 24 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 25 NORTH AMERICA XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023
  • FIGURE 26 EUROPE MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
  • FIGURE 27 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 28 EUROPE XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023
  • FIGURE 29 ASIA PACIFIC MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
  • FIGURE 30 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 31 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 32 SOUTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
  • FIGURE 33 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 34 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 35 MIDDLE EAST AND AFRICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
  • FIGURE 36 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 37 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 38 GLOBAL XEROSIS TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
  • FIGURE 39 COMPETITOR DASHBOARD: GLOBAL XEROSIS TREATMENT MARKET
  • FIGURE 40 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 41 AMGEN INC.: SWOT ANALYSIS
  • FIGURE 42 PROCTER & GAMBLE: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 43 PROCTER & GAMBLE: SWOT ANALYSIS
  • FIGURE 44 UNILEVER: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 45 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 46 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 47 CIPLA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 48 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 49 BAYER AG: SWOT ANALYSIS
  • FIGURE 50 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 51 JOHNSON & JOHNSON INC.: SWOT ANALYSIS
  • FIGURE 52 GALDERMA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 53 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT